Thimble Bioelectronics ENSO device uses high-frequency impulse therapy (HFIT) to help patients manage chronic pain issues without the need for medicines or surgery.
The ENSO smartphone app lets you control your ENSO HFIT™ device and switch between multiple ENSO HFIT™ devices. The FDA has also cleared the device for the treatment of chronic pain.
Related Reading
- This FDA-Approved Gadget Treats Migraines Without Medicine
- Fitbit assisting Cedars-Sinai Medical Center with a VR based therapy for chronic low back pain
- Apple’s 2020 Health partnerships begin to take shape in the area of post-surgical care and mobility
- Abbott Launches Neurosphere Mypath digital health app for pain management
How Thimble helps patients manage chronic pain issues without the need for medicines or surgery
According to the manufacturer, ENSO HFIT™ is a non-invasive device shown in double-blind clinical trials to reduce pain by 56% and deliver clinically effective relief for 86% of patients.
Thimble has also signed up with Harvard Medical school to study the impact of high-frequency impulse therapy for Neuropathic pain.
The National Institute of Neurological Disorders and Stroke (NINDS) reported that 20 million Americans have peripheral neuropathy.
This is a common problem for patients who have suffered a stroke, have diabetes, or undergone chemotherapy.
Current drugs help but often fail to offer relief for many patients
Today’s standard course of treatment for neuropathic pain is either Gabapentin or Pregabalin, and each of these drugs has its own side effects.
This latest clinical study is being sponsored by Harvard Medical school with the collaboration of Thumble Bioelectronics.
Clinical study objectives
This latest clinical trial’s objective is to determine whether self-administered, at-home use of ENSO therapy, a high-frequency impulse neuromodulation device, is an effective, acceptable, and feasible method of relief from neuropathic pain among patients with Neuromyelitis Optica spectrum disorder (NMOSD).
Although there are many devices out there that provide transcutaneous electrical nerve stimulation (e.g., TENS unit), ENSO has evolved to be a leader in this space after working with different clinicians and proving their product via numerous clinical trials.
The possibility that users can manage chronic pain associated with Neuropathy by using a non-invasive wearable is definitely great news. Hopefully, it results in bringing both relief and hope to many patients who suffer from neuropathy.
